- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest
Journal of Law, Medicine and Ethics 49 (1):39-49 (2021)
Abstract
Enhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.My notes
Similar books and articles
Considerations for applying bioethics norms to a biopharmaceutical industry setting.Wendell Fortson, Kathleen Novak Stern, Curtis Chang, Angela Rossetti, Ariella Kelman, Michael Turik, Donald G. Therasse, Tatjana Poplazarova & Luann E. Van Campen - 2021 - BMC Medical Ethics 22 (1).
Open innovation model within public research and innovation programmes.Mateusz Bonecki - 2016 - Filozofia Publiczna I Edukacja Demokratyczna 5 (2):171-188.
why responsible innovation.Rene Von Schomberg - 2019 - In René von Schomberg & Jonathan Hankins (eds.), International Handbook on Responsible Innovation. A global resource. Cheltenham, Royaume-Uni: Edward Elgar Publishing. pp. 12-32.
The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.Bhaven N. Sampat - 2021 - Journal of Law, Medicine and Ethics 49 (1):10-18.
National Innovation System: The System Approach in Historical Perspective.Benoît Godin - 2009 - Science, Technology, and Human Values 34 (4):476-501.
Conflicts of interest in e‐cigarette research: A public good and public interest perspective.Benjamin Capps, Yvette van der Eijk & Timothy M. Krahn - 2019 - Bioethics 34 (1):114-122.
Biopharmaceutical Innovation Capacities – Benchmarking Europe and Implications for CEE.Sibylle Gaisser & Thomas Reiss - 2008 - Law and Ethics of Human Rights 2 (2).
Innovation systems in Malaysia: a perspective of university—industry R&D collaboration. [REVIEW]V. G. R. Chandran, Veera Pandiyan Kaliani Sundram & Sinnappan Santhidran - 2014 - AI and Society 29 (3):435-444.
Serving the public and serving the market: A conflict of interest?John McManus - 1992 - Journal of Mass Media Ethics 7 (4):196 – 208.
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry. [REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.
Industry, innovation and social values.Dr Harvey E. Bale Jr - 2005 - Science and Engineering Ethics 11 (1):31-40.
The Stakes in Bayh-Dole: Public Values Beyond the Pace of Innovation.Walter D. Valdivia - 2011 - Minerva 49 (1):25-46.
Identification of Driving Factors of Scientific and Technological Innovation in the New Material Industry Based on the Theory of Complex Adaptive System: Taking the Construction of Green Innovation System as an Example.Tengfei Ma & Chao Liu - 2021 - Complexity 2021:1-12.
Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
Is risk regulation a strategic influence on decision making in the biotechnology industry?Joanna Chataway & Joyce Tait - 1993 - Agriculture and Human Values 10 (2):60-67.
Analytics
Added to PP
2021-04-22
Downloads
19 (#746,429)
6 months
8 (#274,950)
2021-04-22
Downloads
19 (#746,429)
6 months
8 (#274,950)
Historical graph of downloads
Citations of this work
INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges.Ameet Sarpatwari & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (1):6-9.
References found in this work
The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.Catherine M. Montgomery & Javier Lezaun - 2015 - Science, Technology, and Human Values 40 (1):3-29.
What Will It Take to Address the Global Threat of Antibiotic Resistance?Steven J. Hoffman & Kevin Outterson - 2015 - Journal of Law, Medicine and Ethics 43 (2):363-368.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-6d9b7f7c4c-sqt28 uwo